Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883153 | 0.93 | SIGMAR1 (0.49) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4889873 | 0.88 | MEN1 (0.56) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4890266 | 0.87 | MEN1 (0.58) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4881797 | 0.87 | MEN1 (0.58) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4889264 | 0.86 | TSHR (0.53) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4885076 | 0.86 | MEN1 (0.54) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4889974 | 0.85 | MEN1 (0.53) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4882542 | 0.84 | MEN1 (0.71) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4889815 | 0.84 | MEN1 (0.52) | CHRM3MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL4887153 | 0.83 | CHRM3 (0.50) | CHRM3MEN1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | claimed |
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885MEN1 1629/4885KMT2A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.